XML 35 R25.htm IDEA: XBRL DOCUMENT v3.23.1
2. Fair Value Measurements (Tables)
 3 Months Ended 6 Months Ended
Mar. 31, 2023
Jun. 30, 2022
Fair Value Disclosures [Abstract]    
Debt Securities, Available-for-sale [Table Text Block]
Available-for-sale investments consist of the following (in millions):
 March 31, 2023
Amortized
Cost		Unrealized
Gains		Unrealized
Losses		Allowances for Credit Losses
Fair
Value
Short-term investments:    
Corporate debt securities$682.8 $0.4 $(9.0)$— $674.2 
Municipal obligations18.2 — (0.2)— 18.0 
Asset-backed securities333.4 0.3 (5.6)— 328.1 
U.S. government sponsored agencies295.9 0.2 (2.4)— 293.7 
Foreign government obligations13.8 — (0.2)— 13.6 
 $1,344.1 $0.9 $(17.4)$— $1,327.6 
Available-for-sale investments consist of the following (in millions):
 December 31, 2022
Amortized
Cost		Unrealized
Gains		Unrealized
Losses		Allowances for Credit LossesEstimated
Fair
Value
Short-term investments:    
Corporate debt securities$709.9 $0.2 $(10.8)— $699.3 
Municipal obligations23.4 — (0.3)— 23.1 
Asset-backed securities339.6 0.1 (6.3)— 333.4 
U.S. government sponsored agencies233.9 — (3.2)— 230.7 
Foreign government obligations13.8 — (0.3)— 13.5 
Total1,320.6 0.3 (20.9)— 1,300.0 
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]
Level 2 Fair Value Measurements

To estimate the fair value of Level 2 debt securities as of March 31, 2023, our primary pricing provider uses Refinitiv as the primary pricing source. Our pricing process allows us to select a hierarchy of pricing sources for securities held. If Refinitiv does not price a Level 2 security that we hold, then the pricing provider will utilize our custodian supplied pricing as the secondary pricing source.

Available-for-sale investments consist of the following (in millions):
 March 31, 2023
Amortized
Cost		Unrealized
Gains		Unrealized
Losses		Allowances for Credit Losses
Fair
Value
Short-term investments:    
Corporate debt securities$682.8 $0.4 $(9.0)$— $674.2 
Municipal obligations18.2 — (0.2)— 18.0 
Asset-backed securities333.4 0.3 (5.6)— 328.1 
U.S. government sponsored agencies295.9 0.2 (2.4)— 293.7 
Foreign government obligations13.8 — (0.2)— 13.6 
 $1,344.1 $0.9 $(17.4)$— $1,327.6 
The following is a summary of the amortized cost and estimated fair value of our debt securities at March 31, 2023 by contractual maturity date (in millions):
Amortized
Cost		Estimated Fair
Value
Mature in less than one year$412.5 $409.1 
Mature in one to five years777.2 767.7 
Mature in more than five years154.4 150.8 
Total$1,344.1 $1,327.6 

Available-for-sale investments consist of the following (in millions):
 December 31, 2022
Amortized
Cost		Unrealized
Gains		Unrealized
Losses		Allowances for Credit LossesEstimated
Fair
Value
Short-term investments:    
Corporate debt securities$709.9 $0.2 $(10.8)— $699.3 
Municipal obligations23.4 — (0.3)— 23.1 
Asset-backed securities339.6 0.1 (6.3)— 333.4 
U.S. government sponsored agencies233.9 — (3.2)— 230.7 
Foreign government obligations13.8 — (0.3)— 13.5 
Total1,320.6 0.3 (20.9)— 1,300.0 

As of March 31, 2023 there were no significant continuous unrealized losses greater than 12 months.
Our evaluation of credit losses for available-for-sale debt securities included the extent to which the fair value is less than the amortized cost basis, adverse conditions specifically related to the debt security, an industry or geographic area, and any changes in the rating of a security by a rating agency. Credit loss impairments are limited to the amount that the fair value of an instrument is less than its amortized cost basis.

At March 31, 2023, we have concluded that all payments related to our available-for-sale investments are expected to be made in full and on time at par value. The diminution of value in the intervening period is due to market conditions such as illiquidity and interest rate movements and not due to significant, inherent credit concerns surrounding the issuer. As a result, we have no allowances for credit losses on our available-for-sale investments portfolio as of March 31, 2023.
Included in other current assets are $14.8 million and $11.6 million of interest receivable as of March 31, 2023 and December 31, 2022, respectively, primarily associated with securities in our available-for-sale investments portfolio. The interest on these securities is typically payable semi-annually. Due to the short-term nature of our interest receivable asset, we have made an accounting policy election not to measure an allowance for credit losses for accrued interest receivable. We consider any uncollected interest receivable that is overdue greater than one year to be impaired for purposes of write-off. For the three months ended March 31, 2023, we have not written-off any uncollected interest receivable.
As part of distributing our products, we regularly enter into intercompany transactions. We enter into forward foreign exchange contracts to manage foreign exchange risk of future movements in foreign exchange rates that affect foreign currency denominated intercompany receivables and payables. We do not use derivative financial instruments for speculative or trading purposes. We do not seek hedge accounting treatment for these contracts.  As a result, these contracts, generally with maturity dates of 90 days or less, are recorded at their fair value at each balance sheet date. The notional amounts provide one measure of foreign exchange exposures as of March 31, 2023 and do not represent the amount of Bio-Rad's exposure to loss. The estimated fair value of these contracts was derived using the spot rates and forward points from Refinitiv on the last business day of the quarter. The resulting gains or losses from foreign exchange contracts offset gains or losses from foreign currency remeasurement of the related receivables and payables, both of which are included in Foreign currency exchange (gains) losses, net in the condensed consolidated statements of income (loss).

The following is a summary of our forward foreign exchange contracts (in millions):
 March 31,
 2023
Contracts maturing in April through June 2023 to sell foreign currency: 
Notional value$719.5 
Unrealized gain$0.2 
Contracts maturing in April through June 2023 to purchase foreign currency: 
Notional value$84.9 
Unrealized gain$0.2 
  
Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]
Level 3 Fair Value Investments

During the fourth quarter of 2021, we extended a collateralized loan to Sartorius-Herbst Beteiligungen II Gmbh ("SHB"), a private limited company incorporated under the laws of Germany, with a principal amount of €400 million due on January 31, 2029, subject to certain events which could trigger payment prior to maturity (the “Loan”). SHB used the Loan proceeds to partially finance the acquisition of interests under the Sartorius family trust (“Trust”) from a beneficiary of the Trust. The Loan is collateralized by the pledge of certain of the Trust interests, which upon termination of the Trust in mid-2028 represent the right to receive Sartorius ordinary shares. Interest on the loan is payable annually in arrears at 1.5% per annum, and the entire principal amount is due at maturity. In addition to contractual interest, we are entitled to certain value appreciation rights associated with the acquired Trust interests, which upon termination of the Trust represent the right to receive Sartorius ordinary shares, that is due upon repayment of the Loan. We elected the fair value option under ASC 825, Financial Instruments for accounting of the Loan to SHB to simplify the accounting. The fair value of the Loan and value appreciation right is estimated under the income approach using a discounted cash flow, and option pricing model, respectively, which results in a fair value measurement categorized in Level 3. The significant assumptions used to estimate fair value of the Loan include an estimate of the discount rate and cash flows of the Loan and the significant assumptions used to estimate the fair value of the value appreciation right include volatility, the risk-free interest rate, expected life (in years) and expected dividend. The inputs are subject to estimation uncertainty and actual amounts realized may materially differ. An increase in the expected volatility may result in a significantly higher fair value, whereas a decrease in expected life may result in a significantly lower fair value. All subsequent changes in fair value of the Loan and value appreciation right, including accrued interest are recognized in Losses from change in fair market value of equity securities and loan receivable in our condensed consolidated statements of income (loss). The overall change in fair market value reflected in Losses from change in fair market value of equity securities and loan receivable during the three months ended March 31, 2023 was $2.2 million, which includes an $8.0 million gain from the change in fair market value for the Loan offset by a $10.2 million loss from the change in fair market value of the value appreciation right. The decrease in the fair market value of the value appreciation right was due to a decline in the value of the Sartorius ordinary shares. As of March 31, 2023, the €400 million principal amount of the loan is still due on January 31, 2029.
The following table provides a reconciliation of the Level 3 Loan measured at estimated fair value (in millions):

December 31, 2022$322.6 
Net decrease in estimated fair market value of the loan included in Gains (losses) in fair market value of equity securities and loan receivable$(2.2)
Foreign currency exchange gains (losses), net$4.1 
March 31, 2023$324.5 
  
Discussion of current derivative risk management
The following is a summary of our forward foreign exchange contracts (in millions):
 March 31,
 2023
Contracts maturing in April through June 2023 to sell foreign currency: 
Notional value$719.5 
Unrealized gain$0.2 
Contracts maturing in April through June 2023 to purchase foreign currency: 
Notional value$84.9 
Unrealized gain$0.2 
  
Summary of amortized cost and estimated fair value of debt securities by contractual maturity date
The following is a summary of the amortized cost and estimated fair value of our debt securities at March 31, 2023 by contractual maturity date (in millions):
Amortized
Cost		Estimated Fair
Value
Mature in less than one year$412.5 $409.1 
Mature in one to five years777.2 767.7 
Mature in more than five years154.4 150.8 
Total$1,344.1 $1,327.6 
  
Fair Value Measurements, Recurring and Nonrecurring
Financial assets and liabilities carried at fair value and measured on a recurring basis as of March 31, 2023 are classified in the hierarchy as follows (in millions):
Level 1Level 2Level 3Total
Financial assets carried at fair value:
Cash equivalents:
Commercial paper$— $1.5 $— $1.5 
Time deposits— 44.0 — 44.0 
Asset-backed securities— 3.1 — 3.1 
U.S. government sponsored agencies— 20.7 — 20.7 
Money market funds35.9 — — 35.9 
Total cash equivalents (a)35.9 69.3 — 105.2 
Restricted investments (b)7.0 — — 7.0 
Equity securities (c)8,571.6 — — 8,571.6 
Loan under the fair value option (d)— — 324.5 324.5 
Available-for-sale investments:
Corporate debt securities— 674.2 — 674.2 
U.S. government sponsored agencies— 293.7 — 293.7 
Foreign government obligations— 13.6 — 13.6 
Municipal obligations— 18.0 — 18.0 
Asset-backed securities— 328.1 — 328.1 
Total available-for-sale investments (e)— 1,327.6 — 1,327.6 
Forward foreign exchange contracts (f)— 1.4 — 1.4 
Total financial assets carried at fair value$8,614.5 $1,398.3 $324.5 $10,337.3 
Financial liabilities carried at fair value:   
Forward foreign exchange contracts (g)$— $1.1 $— $1.1 
Contingent consideration (h)— — 36.4 36.4 
Total financial liabilities carried at fair value$— $1.1 $36.4 $37.5 
Financial assets and liabilities carried at fair value and measured on a recurring basis as of December 31, 2022 are classified in the hierarchy as follows (in millions):
Level 1Level 2Level 3Total
Financial assets carried at fair value:
Cash equivalents:
Commercial paper$— $21.1 $— $21.1 
Time deposits5.7 — — 5.7 
Asset-backed securities— 1.4 — 1.4 
U.S. government sponsored agencies— 6.0— 6.0 
Money market funds31.5 — — 31.5 
Total cash equivalents (a)37.2 28.5 — 65.7 
Restricted investments (b)6.8 — — 6.8 
Equity securities (c)8,530.4 — — 8,530.4 
Loan under the fair value option (d)— — 322.6 322.6 
Available-for-sale investments:
Corporate debt securities— 699.3 — 699.3 
U.S. government sponsored agencies— 230.7 — 230.7 
Foreign government obligations— 13.5 — 13.5 
Municipal obligations— 23.1 — 23.1 
Asset-backed securities— 333.4 — 333.4 
Total available-for-sale investments (e)— 1,300.0 — 1,300.0 
Forward foreign exchange contracts (f)— 1.5 — 1.5 
Total financial assets carried at fair value$8,574.4 $1,330.0 $322.6 $10,227.0 
Financial liabilities carried at fair value:
Forward foreign exchange contracts (g)$— $6.2 $— $6.2 
Contingent consideration (h)— — 35.6 35.6 
Total financial liabilities carried at fair value$— $6.2 $35.6 $41.8 

(a)Cash equivalents are included in Cash and cash equivalents in the condensed consolidated balance sheets.

(b) Restricted investments are included in the following accounts in the condensed consolidated balance sheets (in millions):
March 31, 2023December 31, 2022
Restricted investments$5.6 $5.6 
Other investments1.4 1.2 
    Total$7.0 $6.8 

(c) Equity securities are included in the following accounts in the condensed consolidated balance sheets (in millions):
March 31, 2023December 31, 2022
Short-term investments$59.7 $56.5 
Other investments8,511.9 8,473.9 
        Total$8,571.6 $8,530.4 

(d) The Loan under the fair value option is included in Other investments in the condensed consolidated balance sheets.
(e) Available-for-sale investments are included in Short-term investments in the condensed consolidated
balance sheets.

(f) Forward foreign exchange contracts in an asset position are included in Other current assets in the condensed consolidated balance sheets.

(g) Forward foreign exchange contracts in a liability position are included in Other current liabilities in the condensed consolidated balance sheets.

(h) Contingent considerations in a liability position are included in Other long-term liabilities in the condensed consolidated balance sheets. Changes in the fair value of contingent consideration are included in Selling, general and administrative expenses in our condensed consolidated statements of income (loss).

Level 1 Fair Value Measurements

As of March 31, 2023, we own 12,987,900 ordinary voting shares and 9,588,908 preference shares of Sartorius AG (Sartorius), of Goettingen, Germany, a process technology supplier to the biotechnology, pharmaceutical, chemical and food and beverage industries. We own approximately 38% of the ordinary outstanding shares (excluding treasury shares) and 28% of the preference shares of Sartorius as of March 31, 2023. The Sartorius family trust (Sartorius family members are beneficiaries of the trust) holds a majority interest of the outstanding ordinary shares of Sartorius. We do not have the ability to exercise significant influence over the operating and financial policies of Sartorius primarily because we do not have any representative or designee on Sartorius' board of directors and have tried and failed to obtain access to operating or financial information necessary to apply the equity method of accounting.

The changes in fair market value of our investment in Sartorius for the three months ended March 31, 2023 was a $20.1 million loss and was recorded in our condensed consolidated statements of income (loss).